The receptor for hyaluronan-mediated motility (RHAMM) is frequently overexpressed in brain tumors and was recently identified as an immunogenic antigen by using serological screening of cDNA expression libraries. In this study, which was conducted using a mouse glioma model, the authors tested the hypothesis that vaccination with dendritic cells transfected with RHAMM mRNA induces strong immunological antitumor effects.
The authors constructed a plasmid for transduction of the mRNAs transcribed in vitro into dendritic cells, which were then used to transport the intracellular protein RHAMM efficiently into major histocompatibility complex class II compartments by adding a late endosomal–lysosomal sorting signal to the RHAMM gene. The dendritic cells transfected with this RHAMM mRNA were injected intraperitoneally into the mouse glioma model 3 and 10 days after tumor cell implantation. The antitumor effects of the vaccine were estimated by the survival rate, histological analysis, and immunohistochemical findings for immune cells.
Mice in the group treated by vaccination therapy with dendritic cells transfected with RHAMM mRNA survived significantly longer than those in the control groups. Immunohistochemical analysis revealed that greater numbers of T lymphocytes containing T cells activated by CD4+, CD8+, and CD25+ were found in the group vaccinated with dendritic cells transfected with RHAMM mRNA.
These results demonstrate the therapeutic potential of vaccination with dendritic cells transfected with RHAMM mRNA for the treatment of malignant glioma.
Abbreviations used in this paper:MHC = major histocompatibility complex; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; RHAMM = receptor for hyaluronan-mediated motility.
Address reprint requests to: Koji Kajiwara, M.D., Department of Neurosurgery, Yamaguchi University School of Medicine, 1-1-1, Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan. email:
AokiHMizunoMNatsumeATsugawaTTsujimuraKTakahashiT: Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother50:463–4682001
FrauwirthKShastriN: Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains. Immunology102:405–4152001
FukuiMUenoKSuehiroYHamanakaYImaiKHinodaY: Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells. Cancer Immunol Immunother55:538–5462006
HeimbergerABArcherGECrottyLEMcLendonREFriedmanAHFriedmanHS: Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery50:158–1662002
KerblatITongiani-DahshanSAude-GarciaCVilliersMDrouetCMarchePN: Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized CD8+ or CD4+ T lymphocytes. Immunology100:178–1842000
KobayashiTYamanakaRHommaJTsuchiyaNYajimaNYoshidaS: Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother52:632–6372003
NowakAKLakeRAMarzoALScottBHeathWRCollinsEJ: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol170:4905–49132003
OrangeDEJegathesanMBlachereNEFrankMOScherHIAlbertML: Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis7:63–722004
SaitoRMizunoMNakaharaNTsunoTKumabeTYoshimotoT: Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer111:777–7822004
Schuler-ThurnerBSSchultzESBergerTGWeinlichGEbnerSWoerlP: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med195:1279–12882002
YamanakaRYajimaNTsuchiyaNHonmaJTanakaRRamseyJ: Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. J Neurosurg97:1184–11902002
YamanakaRZulloSATanakaRBlaeseMXanthopoulosKG: Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA. J Neurosurg94:474–4812001
YangTWithamTFVillaLErffMAttanucciJWatkinsS: Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res62:2583–25912002
YuJSWheelerCJZeltzerPMYingHFingerDNLeePK: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res61:842–8472001